Medical Incubator Japan

The firm emphasizes a global search capability sourced through its network of healthcare specialists. Its deal flow spans academic spinouts and early-stage biotech, often originating from university research labs. For example, portfolio company Heartseed was commercialized from seed technology developed in Professor Fukuda's laboratory at Keio University.

No. While the firm is headquartered in Tokyo, its portfolio includes companies in the United States (DiscGenics, IgGenix), Europe — including Cytospire Therapeutics and ILC Therapeutics in the United Kingdom, Hoba Therapeutics in Denmark — and Japan. The firm's investment scope is global, with a regulatory path that typically includes both Japanese and US or European approval strategies.

桂淳 serves as CEO and leads the firm alongside Chairman 秦充洋. The investment team includes titled Investment Officers 原田謙治 and 安江滋, supported by three principals — 駒澤明日香, 唐瓏, and 栗原大. No investment committee structure is publicly detailed, but authority appears concentrated within this core team of healthcare investment professionals.

The firm invests from seed and startup stage through to pre-IPO opportunities. Its portfolio includes companies at clinical trial stages, such as IgGenix (Phase 1 enrollment completed in September 2025), as well as public companies it backed earlier, including CareNet (TSE Prime), SanBio (TSE Growth), Modalis (TSE Growth), and Heartseed (TSE Growth).

The firm does not publish a list of excluded sectors, but its disclosed portfolio reveals a strict focus on therapeutic drug development and digital health services. There is no evidence of investment in medical devices outside the therapeutic context, diagnostics, or healthcare IT platforms that are not directly linked to drug development or physician enablement.

The firm describes itself as an investment operating company specializing in healthcare. It blends a private equity investment mandate with commercialization support, assisting portfolio companies navigating Japan's Pharmaceuticals and Medical Devices Agency. In February 2024, it also launched a separate business initiative aimed at reducing 'drug loss' — accelerating access to new drugs in Japan — which suggests an operating structure that goes beyond pure fund management.

The firm's public materials do not detail a co-investment program. Portfolio disclosures show direct investments into startup equity; there is no mention of participating in syndicates or fund-of-fund commitments managed by third-party general partners. Its model appears built around proprietary, direct deal execution.